Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylazine SCHEMBL38986 | 0.98 | LMNA (1.00) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL1119093 | 0.98 | LMNA (1.00) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL22616146 | 0.98 | LMNA (0.97) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL18988891 | 0.98 | LMNA (0.97) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL1228390 | 0.98 | LMNA (1.00) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL3339638 | 0.97 | LMNA (0.94) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL9808825 | 0.91 | LMNA (0.83) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL22616203 | 0.91 | RAB9A (0.83) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL22616197 | 0.91 | LMNA (0.83) | LMNACYP3A4CYP2D6TSHRRAB9A | |
| Xylazine SCHEMBL22616093 | 0.90 | LMNA (0.81) | LMNACYP3A4CYP2D6TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 58450 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4727556-A2 | SEQUESTRANT COMPOUNDS FOR ALPHA 2 ADRENERGIC AGONISTS | Clear Scientific, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724125-A1 | APPARATUS, METHODS, AND SYSTEMS FOR ATOMIZED DELIVERY OF A COMPOSITION TO A PATIENT | Microneb Tech Holdings, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4698287-A1 | ANTIMICROBIAL AND DRUG-NEUTRALIZING COMPOSITION | SoRite, LLC (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260047623-A1 | GLOVE HAVING DRUG-DETECTION COATING | SUMMIT GLOVE INC. (US) | 2026-02-19 | — | — | US | claimed |
| WO-2025245294-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245292-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-0220030-B1 | ORAL DELIVERY SYSTEM | BIOTECHNOLOGY AUSTRALIA PTY. LTD. (AU) | 1991-06-19 | — | — | EP | claimed |
| US-4943428-A | 8-HYDROX-2-(DI-N-PROPYLAMINO)TETRALIN | WRIGHT STATE UNIVERSITY (US) | 1990-07-24 | — | — | US | claimed |
| US-4921853-A | Method for producing analgesia in mammals | MICHIGAN STATE UNIVERSITY (US) | 1990-05-01 | — | — | US | claimed |
| CN-86107590-A | Oral administration system | — | 1987-05-20 | — | — | CN | claimed |
| EP-0220030-A2 | Oral delivery system | BIOTECHNOLOGY AUSTRALIA PTY. LTD. (AU) | 1987-04-29 | — | — | EP | claimed |
| WO-1987002251-A1 | ORAL DELIVERY OF BIOLOGICALLY ACTIVE SUBSTANCES BOUND TO VITAMIN B12, OR ANALOGUES THEREOF | BIOTECHNOLOGY AUSTRALIA PTY. LTD. (AU) | 1987-04-23 | — | — | WO | claimed |
| US-4614798-A | IMPROVED YIELD OF INTERMEDIATE USING TETRAHYDROFURAN OR A MIXTURE OF TOLUENE AND N,N-DIMETHYLACETAMIDE AS SOLVENT | VETAMIX (US) | 1986-09-30 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0138358-A1 | The preparation and use of 2-[2-(1,4-benzodioxanyl)]-2-imidazoline in therapy | Farmos-Yhtyma Oy (FI) | 1985-04-24 | — | — | EP | claimed |
| US-4508715-A | DOPAMINE ANTAGONISTS;OVERDOSE TREATMENT | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1985-04-02 | — | — | US | claimed |